#China #Shanghai #Harbour BioMed #Immunology #Jenny Xie

Harbour BioMed Welcomes Dr. Jenny Xie as Chief Scientific Officer

In a significant move to bolster its leadership team, Harbour BioMed, headquartered in Cambridge, Massachusetts, Rotterdam, and Shanghai, has appointed Dr. Jenny Xie as its new Chief Scientific Officer specializing in Immunology and Head of Global External Innovation. This transition, announced on March 19, 2026, is expected to enhance the company's commitment to pioneering new antibody therapeutics, particularly in the realms of immunology and oncology.

Dr. Xie brings an impressive portfolio of over 25 years of experience in the biopharmaceutical sector. Before her role at Harbour BioMed, she served as the Executive Director and Head of Discovery Immunology at Bristol Myers Squibb. There, she led numerous research projects focusing on autoimmune diseases, overseeing the development from research to clinical application of novel therapeutic modalities. Her previous experiences also include key leadership positions at Merck, where she spearheaded early-stage research and development initiatives.

Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, expressed enthusiasm about Dr. Xie's appointment, stating, "Her vast expertise in drug discovery and development will be vital as we aim to enhance our research and development capabilities. I am confident that her leadership will propel our immunology research and collaborative projects forward as we seek to address patient needs globally."

In her new position, Dr. Xie will be responsible for orchestrating Harbour BioMed's global innovation strategy in immunology. This includes managing ongoing collaborations with significant partners and scouting for new partnership avenues to expand the company’s reach and effectiveness. Additionally, she will oversee operations at the Harbour BioMed-AstraZeneca Innovation Lab located in Beijing, which is integral to the company's strategy for fostering innovation in the field.

"Joining Harbour BioMed represents an exciting opportunity for me, and I look forward to collaborating with a talented group of individuals towards our goal of transforming patient lives through innovative solutions, speed, and global partnerships," Dr. Xie remarked on her new role.

Dr. Xie's educational background is equally impressive. She earned her Ph.D. in Immunology from Boston University School of Medicine, following a bachelor's degree in Biology from Fudan University. Her academic credentials, coupled with her extensive hands-on experience, are expected to be key assets for Harbour BioMed.

Harbour BioMed, publicly traded on the Hong Kong Stock Exchange (HKEX: 02142), is committed to the discovery and development of novel antibody therapeutics in immunology, oncology, and more. The company prides itself on developing a robust pipeline through its proprietary antibody technology platform, Harbour Mice®, enabling the creation of fully human monoclonal antibodies. Additionally, innovative advancements like HBICE® bispecific antibody technology are designed to enhance tumor-killing capabilities beyond what traditional combination therapies can achieve.

As Harbour BioMed continues its mission to revolutionize therapeutic approaches, Dr. Jenny Xie’s addition to the executive team marks a pivotal step in reinforcing its position as a leader in the biopharmaceutical industry. With her strategic oversight, the company's external innovation efforts are expected to bring forth groundbreaking advancements in immunology.

For more information on Harbour BioMed's initiatives and breakthroughs in antibody therapeutics, please visit their official website.